Madrigal Mentalis

Madrigal Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for metabolic, cardiovascular, and liver diseases. The company's lead product, Rezdiffra (resmetirom), is a liver-directed, thyroid hormone receptor (THR)-beta selective agonist designed to target the underlying causes of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. In March 2024, Rezdiffra received accelerated approval from the U.S. FDA, making it the first approved medication for adults with noncirrhotic MASH with moderate to advanced liver fibrosis. Madrigal is currently focused on the commercial launch of Rezdiffra while continuing clinical trials to support full approval and expand the drug's indication to include patients with well-compensated NASH cirrhosis.